FdaApplication
NDA 218808
Identifiers
- fda_app_no: NDA218808
Properties
| Property | Value |
|---|---|
| applicant_name | NEUROCRINE BIOSCIENCES INC |
| application_type | NDA |
| approval_date | 2024-12-13 |
Revenue by product
CRENESSITY
| Period | Revenue |
|---|---|
| Q1 2026 | $153.3M |
| Q1 2025 | $14.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CRENESSITY | CRINECERFONT | 50MG | CAPSULE;ORAL |
| CRENESSITY | CRINECERFONT | 100MG | CAPSULE;ORAL |
| CRENESSITY | CRINECERFONT | 25MG | CAPSULE;ORAL |
3 products